COVID-19 vaccination has entered a different phase in 2026. The emergency period of the pandemic has passed, but SARS-CoV-2 continues to circulate and evolve. Vaccines are therefore no longer discussed only as a response to a global crisis. They are increasingly considered part of longer-term respiratory disease prevention, particularly for people who face a higher risk of severe illness.
The central question has also changed.
Instead of asking whether vaccination can completely prevent infection, researchers and public-health agencies increasingly focus on whether vaccination continues to reduce the risk of serious outcomes and how often formulations should be updated as the virus changes.
Current evidence supports an important role for COVID-19 vaccines in reducing severe disease, particularly among people at higher risk. At the same time, protection against infection can be less consistent and can decline over time.
The World Health Organization’s July 2026 position paper emphasizes sustained SARS-CoV-2 circulation, existing population immunity, and the continued development of variant-adapted vaccines as countries integrate COVID-19 vaccination into longer-term health programs.
How COVID-19 Vaccines Work
COVID-19 vaccines work by preparing the immune system to recognize SARS-CoV-2 and respond more quickly when it encounters the virus.
Several vaccine technologies have been used during the pandemic.
mRNA vaccines provide instructions that allow cells to temporarily produce a harmless component of the virus, prompting an immune response. Protein-based vaccines use selected viral proteins or protein components to stimulate immunity.
The vaccine platforms available in 2026 have changed compared with the earliest stages of the pandemic. According to the WHO’s July 2026 position paper, currently updated WHO-listed vaccines include mRNA and protein-subunit platforms, while earlier inactivated and viral-vector vaccines are no longer being manufactured for WHO-listed use.
The purpose of vaccination is not to create an impenetrable barrier against every infection.
Rather, vaccination helps the immune system respond more effectively, with the strongest public-health benefit being protection against severe COVID-19.
Why Vaccine Formulations Continue to Change
SARS-CoV-2 continues to evolve.
As new lineages emerge, the antibodies generated by previous infection or vaccination may recognize newer variants less effectively than they recognize earlier versions of the virus.
This is one reason vaccine composition is periodically reviewed.
In May 2026, the WHO Technical Advisory Group on COVID-19 Vaccine Composition recommended monovalent LP.8.1 as the preferred vaccine antigen. WHO also stated that other approaches capable of producing broad immune responses against circulating variants could be considered.
Importantly, WHO advised that vaccination should not be delayed simply while waiting for a newer formulation to become available.
The previously recommended JN.1 lineage, including JN.1 and KP.2 formulations, remained suitable alternatives according to WHO guidance.
This illustrates an important point about modern COVID-19 vaccination: the goal is not to find one permanent formulation that never changes. Instead, vaccine composition can be adjusted as scientists monitor the evolution of the virus.
How Effective Are COVID-19 Vaccines?
Vaccine effectiveness varies depending on the outcome being measured.
Protection against infection can be lower and less durable than protection against severe disease. Factors such as age, previous infection, time since vaccination, underlying health conditions, circulating variants, and the specific vaccine formulation can all influence effectiveness.
Real-world studies have continued to find meaningful protection against medically attended illness and hospitalization.
For example, CDC’s evaluation of the 2024–2025 COVID-19 vaccine found approximately 33% effectiveness against COVID-19-associated emergency department or urgent-care visits among adults and about 45% effectiveness against hospitalization among adults aged 65 and older without immunocompromising conditions during the study period.
These figures should not be interpreted as a universal effectiveness number for every person or every 2026 vaccine formulation.
Instead, they demonstrate why vaccine effectiveness needs to be evaluated continuously as populations, vaccines, and circulating variants change.
Protection Against Severe COVID-19 Remains the Main Goal
The most important benefit of vaccination is protection against serious disease.
WHO states that vaccines listed by the organization provide protection against severe COVID-19 and death resulting from the disease. Real-world evidence also continues to show meaningful protection against severe outcomes, including with vaccines adapted to Omicron lineages.
This is especially important for people whose risk increases with age or certain health conditions.
A vaccine does not guarantee that an individual will never become infected. Instead, it can improve the body’s ability to respond to the virus and reduce the likelihood that an infection will progress to a more serious stage.
That distinction is essential when interpreting claims about vaccine effectiveness.
What Happens to Protection Over Time?
Immunity does not remain at exactly the same level indefinitely.
WHO notes that protection can decline over time, which is one reason periodic vaccination may be recommended for groups at higher risk.
The timing of additional doses depends on national recommendations, age, health status, previous vaccination, previous infection, pregnancy, and other factors.
There is therefore no single booster schedule that applies equally to everyone worldwide.
Instead, health authorities increasingly focus vaccination efforts on people most likely to benefit.
Who Is Most Likely to Benefit From Vaccination?
WHO’s updated 2026 recommendations emphasize groups at higher risk of severe COVID-19.
These include the oldest adults and certain older adults with significant health conditions. WHO also recommends consideration of vaccination during pregnancy, with the goal of protecting the pregnant person and providing antibodies to the infant during the early months of life.
Recommendations for children are more selective. WHO’s 2026 guidance states that previously unvaccinated healthy children between 6 and 23 months may be considered for vaccination when there is a significant disease burden in that age group.
National policies can differ because countries consider local disease patterns, healthcare systems, vaccine availability, cost-effectiveness, and population characteristics.
For that reason, people should consult their local health authority or healthcare professional for recommendations applicable to their circumstances.
What Do We Know About Vaccine Safety?
COVID-19 vaccines have now been administered on a very large scale.
WHO reports that serious adverse events remain rare relative to more than 13 billion doses administered globally. Most reported reactions are mild or moderate and temporary, commonly resolving within a few days.
Common short-term reactions can include soreness where the vaccine was given, fatigue, headache, muscle aches, or fever.
As with other medical products, COVID-19 vaccines can have uncommon or rare adverse reactions, and safety monitoring remains an important part of vaccination programs.
The fact that vaccines are widely used does not mean monitoring stops.
Health agencies continue to collect safety information, investigate potential signals, and update recommendations when new evidence becomes available.
Vaccination During Pregnancy
Pregnancy is an important consideration because COVID-19 can pose additional health concerns during pregnancy.
WHO’s 2026 recommendations support one COVID-19 vaccine dose during each pregnancy, regardless of whether the person was previously vaccinated, with timing ideally during the second trimester. The recommendation aims to support protection for the pregnant person and transfer maternal antibodies to the infant.
Individual medical decisions can vary, particularly when someone has specific health circumstances.
Pregnant people should discuss vaccination with a qualified healthcare professional when they need advice tailored to their medical history.
Can Vaccinated People Still Get COVID-19?
Yes.
Breakthrough infections remain possible because vaccination does not provide complete or permanent protection against infection.
SARS-CoV-2 continues to evolve, and some variants can partially evade antibodies generated through earlier vaccination or infection.
This does not mean vaccines have failed.
A vaccine can provide meaningful protection against severe outcomes even when it does not prevent every infection.
The CDC specifically identifies hospitalization, critical illness, and medically attended illness as important outcomes for evaluating COVID-19 vaccine effectiveness.
This is why a realistic description of vaccination should acknowledge both sides: infections can still occur, while the risk of serious disease can be reduced.
Can COVID-19 Vaccines Be Given With Other Vaccines?
Coadministration is another consideration in vaccination programs.
WHO’s 2026 position paper addresses vaccine schedules and coadministration as part of broader COVID-19 vaccination policy.
In many settings, COVID-19 vaccination can be administered during the same visit as other recommended vaccines, depending on national guidance and the individual’s circumstances.
People with questions about receiving multiple vaccines at the same appointment should follow the advice of their healthcare provider or local immunization program.
Why Global Access Still Matters
The scientific development of updated vaccines is only part of the public-health challenge.
Access also matters.
WHO continues to emphasize equitable access to COVID-19 vaccines, particularly for populations at higher risk.
Differences in vaccine availability, healthcare infrastructure, affordability, and delivery systems can influence how effectively countries protect vulnerable populations.
The long-term management of COVID-19 therefore involves more than creating new formulations.
It also requires disease surveillance, vaccination programs, healthcare capacity, public communication, and continued research.
What Researchers Are Watching in 2026
SARS-CoV-2 is unlikely to remain genetically static.
WHO’s vaccine composition group continues to monitor viral evolution, immune responses, and vaccine performance against circulating variants. The organization reviews vaccine composition periodically and can recommend changes when evidence supports them.
Researchers are also interested in developing vaccines that can provide broader and longer-lasting protection.
Other areas of interest include improved understanding of protection against emerging variants, durability of immunity, vaccination strategies for different age groups, and ways to improve global vaccine access.
The future of COVID-19 vaccination is therefore likely to involve continued adaptation rather than a single final vaccine formula.
Understanding the Balance of Benefits and Risks
No medical intervention is completely without potential risks.
At the same time, the risks associated with COVID-19 itself vary substantially among individuals.
Age, underlying health conditions, pregnancy, immune status, and previous immunity can all influence the balance between potential benefits and risks.
This is why modern vaccination recommendations increasingly focus on risk-based strategies rather than assuming that every person has exactly the same need for vaccination at exactly the same interval.
WHO’s 2026 position paper reflects this approach by emphasizing groups at increased risk of severe disease while allowing national programs to adapt recommendations to local circumstances.
Conclusion: What COVID-19 Vaccination Looks Like in 2026
COVID-19 vaccines in 2026 are part of a longer-term strategy for managing a virus that continues to circulate and evolve.
The evidence supports an important role for vaccination in reducing severe COVID-19, hospitalization, and other serious outcomes, particularly among people at higher risk. Protection against infection is less complete and can decline over time, which helps explain the continued development of updated formulations and periodic vaccination recommendations.
The latest WHO guidance also shows how quickly the field continues to evolve. LP.8.1 is the organization’s recommended vaccine antigen as of May 2026, while JN.1-lineage formulations remain suitable alternatives.
The most useful way to understand COVID-19 vaccination today is therefore neither to describe it as perfect nor to dismiss its benefits.
It is a tool whose effectiveness depends on the outcome being measured, the vaccine formulation, the circulating virus, the time since vaccination, and the characteristics of the person receiving it.
As SARS-CoV-2 continues to change, ongoing surveillance and research will remain essential.
For individuals, the most appropriate vaccination schedule should be based on current recommendations in their country and, when necessary, advice from a qualified healthcare professional.
Sources
World Health Organization. “COVID-19 Vaccines.” Updated May 2026. WHO COVID-19 Vaccines Q&A
World Health Organization. “WHO Position Paper on COVID-19 Vaccines – July 2026.” WHO July 2026 Position Paper
World Health Organization. “Statement on the Antigen Composition of COVID-19 Vaccines.” May 16, 2026. WHO Vaccine Composition Statement
World Health Organization. “Immunization, Vaccines and Biologicals: COVID-19.” WHO COVID-19 Vaccine Information
Centers for Disease Control and Prevention. “Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults.” CDC Vaccine Effectiveness Report
Centers for Disease Control and Prevention. “COVID-19 Vaccine Effectiveness.” CDC Vaccine Effectiveness Program